Systematic review and network meta ‐analysis: first‐ and second‐line pharmacotherapy for moderate‐severe ulcerative colitis

ConclusionInfliximab and vedolizumab are ranked highest as first‐line agents, and tofacitinib is ranked highest as second‐line agent, for induction of remission and mucosal healing in patients with moderate‐severe UC, based on indirect comparisons. Head‐to‐head trials are warranted to inform clinical decision‐making with greater confidence.
Source: Alimentary Pharmacology and Therapeutics - Category: Drugs & Pharmacology Authors: Tags: SYSTEMATIC REVIEW WITH META ‐ANALYSIS Source Type: research